Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fresenius kabi deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 100.g; natriumchlorid 9.g

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fresenius kabi deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumacetat-trihydrat, natriumchlorid, kaliumchlorid, magnesiumchlorid-hexahydrat - infusionslösung - hydroxyethylstärke (ph.eur.) 60.g; natriumacetat-trihydrat 4.63g; natriumchlorid 6.02g; kaliumchlorid 0.3g; magnesiumchlorid-hexahydrat 0.3g

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fresenius kabi deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumacetat-trihydrat, natriumchlorid, kaliumchlorid, magnesiumchlorid-hexahydrat - infusionslösung - hydroxyethylstärke (ph.eur.) 60.g; natriumacetat-trihydrat 4.63g; natriumchlorid 6.02g; kaliumchlorid 0.3g; magnesiumchlorid-hexahydrat 0.3g

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fresenius kabi deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 60.g; natriumchlorid 9.g

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fresenius kabi deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 60.g; natriumchlorid 9.g

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fresenius kabi deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 100.g; natriumchlorid 9.g

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ticarcillin sodium, quantity: 3.3 g (equivalent: ticarcillin, qty 3 g); potassium clavulanate, quantity: 119.2 g (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - timentin is indicated in the treatment of serious infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: septicaemia (and bacteraemia) cases caused by beta-lactamase producing organisms including strains of klebsiella pneumoniae, e.coli, staphylococcus aureus and pseudomonas aeruginosa. lower respiratory infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, haemophilus influenzae and klebsiella pneumoniae. bone and joint infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus. skin and skin structure infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, klebsiella pneumoniae and e. coli. urinary tract infections cases caused by beta-lactamase producing susceptible organisms including strains of e.coli, klebsiella pneumoniae, pseudomonas aeruginosa and staphylococcus au

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for injection - 2000 mg - active: ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 200 mg/ml;   - powder for oral suspension - 200 mg/ml - active: mycophenolate mofetil 200 mg/ml   excipient: aspartame citric acid colloidal silicon dioxide fruit mix flavour 274869 lecithin methyl hydroxybenzoate sodium citrate dihydrate sorbitol xanthan gum - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ertapenem sodium 209.2 mg/ml equivalent to 200 mg/ml ertapenem free acid - powder for injection - 200 mg/ml - active: ertapenem sodium 209.2 mg/ml equivalent to 200 mg/ml ertapenem free acid excipient: sodium bicarbonate sodium hydroxide water for injection - treatment invanz is indicated for the treatment of patients with moderate to severe infections caused by susceptible strains of micro-organisms, as well as initial empiric therapy prior to the identification of causative organisms in the infections listed below: · complicated intra-abdominal infections · complicated skin and skin structure infections including diabetic lower extremity and diabetic foot infections · community acquired pneumonia · complicated urinary tract infections including pyelonephritis · acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynaecologic infections · bacterial septicaemia prevention invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.